| AYJ Stock | | | EUR 1.97 0.03 1.50% |
Executive
Ms. AnneMarie Graffin was Independent Member of the Supervisory Board of VALNEVA SE since March 7, 2013. Ms. Graffin is Member of company Nominating and Remuneration Committee. She serves as Member of the Supervisory Board at NANOBIOTIX S.A., NonExecutive Independent Director at SARTORIUS STEDIM BIOTECH S.A. and Manager of SARL SMAG Consulting. She holds degree from ESSEC Business School. since 2013.
| Age | 58 |
| Tenure | 11 years |
| Phone | 33 2 28 07 37 10 |
| Web | https://valneva.com |
Valneva SE Management Efficiency
The company has return on total asset
(ROA) of
(0.185) % which means that it has lost $0.185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(1.8614) %, meaning that it generated substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities.
Valneva SE has accumulated 50.73
M in total debt with debt to equity ratio
(D/E) of 1.45, which is about average as compared to similar companies. Valneva SE has a current ratio of 1.21, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Valneva SE until it has trouble settling it off, either with new capital or with free cash flow. So, Valneva SE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valneva SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valneva to invest in growth at high rates of return. When we think about Valneva SE's use of debt, we should always consider it together with cash and equity.
Similar Executives
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France. VALNEVA SE is traded on Frankfurt Stock Exchange in Germany. Valneva SE (AYJ) is traded on Frankfurt Exchange in Germany and employs 762 people.
Management Performance
Valneva SE Leadership Team
Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic Jacotot, Vice President, General Counsel, Member of the Management Board, Member of the Executive Committee , General Secretary | |
| AnneMarie Graffin, Independent Member of the Supervisory Board | |
| Johanna Pattenier, Member of the Supervisory Board | |
| Thomas Lingelbach, Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board | |
| Louisa ShawMarotto, Vice Chairman of the Supervisory Board, Independent Director | |
| Gerald Strohmaier, VP Resource | |
| Frances Muir, Site Director Livingston, Member of the Executive Committee | |
| Peter Buhler, CFO Member | |
| Wolfgang Bender, Chief Medical Officer, Member of the Management Board, Member of the Executive Committee | |
| Joshua Drumm, VP Relations | |
| Dipal Patel, Chief Board | |
| Franck Grimaud, Chief Executive Officer, Member of the Management Board, Member of the Executive Committee | |
| Janet Hoogstraate, Chair of the Management Board of Valneva Sweden AB, Member of the Executive Committee | |
| James Sulat, Independent Vice Chairman of the Supervisory Board | |
| Franck MBA, Chief Gen | |
| Frederic Grimaud, Chairman of the Supervisory Board | |
| Juan Jaramillo, Chief Medical Officer, Member of the Management Board | |
| David Lawrence, Chief Financial Officer, Member of the Management Board | |
| Klaus Schwamborn, Vice President - Discovery Research & Innovation, Member of the Executive Committee | |
| JuanCarlos MD, Chief Board | |
| Michael Moehlen, Vice President Corporate Technical Development, Member of the Executive Committee | |
| Andreas Meinke, Vice President Pre-clinical & Translational Research, Member of the Executive Committee | |
| Perry Celentano, Interim Chief Operating Officer | |
| Olivier Jankowitsch, Vice President Global Supply Operations, Member of the Executive Committee | |
| Laetitia BachelotFontaine, Investor Relations Manager | |
| Manfred Tiefenbacher, Vice President - Finance, Member of the Executive Committee | |
| Thomas Casdagli, Member of the Supervisory Board - Representative of MVM Partners LLP | |
| Jason Golan, Vice President Commercial Operations, Member of the Executive Committee | |
| Sharon Tetlow, Member of the Supervisory Board | |
Valneva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Valneva Stock
Valneva SE financial ratios help investors to determine whether Valneva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valneva with respect to the benefits of owning Valneva SE security.